The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura
Open accessAbstract
BACKGROUND: In acquired thrombotic thrombocytopenic purpura (TTP), an immune-mediated deficiency of the von Willebrand factor-cleaving protease ADAMTS13 allows unrestrained adhesion of von Willebrand factor multimers to platelets and microthrombosis, which result in thrombocytopenia, hemolytic anemia, and tissue ischemia. Caplacizumab, an anti-von Willebrand factor humanized, bivalent variable-domain-only immunoglobulin fragment, inhibits interaction between von Willebrand factor multimers and platelets. METHODS: In this double-blind, controlled trial, we randomly assigned 145 patients with TTP to receive caplacizumab (10-mg intravenous loading bolus, followed by 10 mg daily subcutaneously) or placebo during plasma exchange and for 30 days thereafter. The primary outcome was the time to normalization of the platelet count, with discontinuation of daily plasma exchange within 5 days thereafter. Key secondary outcomes included a composite of TTP-related death, recurrence of TTP, or a thromboembolic event during the trial treatment period; recurrence of TTP at any time during the trial; refractory TTP; and normalization of organ-damage markers. RESULTS: The median time to normalization of the platelet count was shorter with caplacizumab than with placebo (2.69 days [95% confidence interval {CI}, 1.89 to 2.83] vs. 2.88 days [95% CI, 2.68 to 3.56], P=0.01), and patients who received caplacizumab were 1.55 times as likely to have a normalization of the platelet count as those who received placebo. The percentage of patients with a composite outcome event was 74% lower with caplacizumab than with placebo (12% vs. 49%, P<0.001). The percentage of patients who had a recurrence of TTP at any time during the trial was 67% lower with caplacizumab than with placebo (12% vs. 38%, P<0.001). Refractory disease developed in no patients in the caplacizumab group and in three patients in the placebo group. Patients who received caplacizumab needed less plasma exchange and had a shorter hospitalization than those who received placebo. The most common adverse event was mucocutaneous bleeding, which was reported in 65% of the patients in the caplacizumab group and in 48% in the placebo group. During the trial treatment period, three patients in the placebo group died. One patient in the caplacizumab group died from cerebral ischemia after the end of the treatment period. CONCLUSIONS: Among patients with TTP, treatment with caplacizumab was associated with faster normalization of the platelet count; a lower incidence of a composite of TTP-related death, recurrence of TTP, or a thromboembolic event during the treatment period; and a lower rate of recurrence of TTP during the trial than placebo. (Funded by Ablynx; HERCULES ClinicalTrials.gov number, NCT02553317 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rock, G. A., Shumak, K. H., Buskard, N. A., Blanchette, V. S., Kelton, J. G., Nair, R. C., & Spasoff, R. A. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108083250604 · Cited by 1,920
Scully, M., Hunt, B. J., Benjamin, S., Liesner, R., Rose, P., Peyvandi, F., Cheung, B., Machin, S. J., & on behalf of British Committee for Standards in Haematology (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09167.x · Cited by 863
Self-citationThrombotic thrombocytopenic purpura
Joly, B. S., Coppo, P., & Veyradier, A. (2017) · Blood · doi:10.1182/blood-2016-10-709857 · Cited by 716
Self-citationCaplacizumab for Acquired Thrombotic Thrombocytopenic Purpura
Peyvandi, F., Scully, M., Kremer Hovinga, J. A., Cataland, S., Knöbl, P., Wu, H., Artoni, A., Westwood, J.-P., Mansouri Taleghani, M., Jilma, B., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505533 · Cited by 666
Self-citationVon Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura
Sadler, J. E. (2008) · Blood · doi:10.1182/blood-2008-02-078170 · Cited by 574
Survival and relapse in patients with thrombotic thrombocytopenic purpura
Hovinga, J. A. K., Vesely, S. K., Terrell, D. R., Lämmle, B., & George, J. N. (2010) · Blood · doi:10.1182/blood-2009-09-243790 · Cited by 574
Leebeek, F. W. G., & Eikenboom, J. C. J. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1601561 · Cited by 567
Scully, M., Cataland, S., Coppo, P., de la Rubia, J., Friedman, K. D., Kremer Hovinga, J., Lämmle, B., Matsumoto, M., Pavenski, K., Sadler, E., et al. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13571 · Cited by 506
Self-citationDeford, C. C., Reese, J. A., Schwartz, L. H., Perdue, J. J., Kremer Hovinga, J. A., Lämmle, B., Terrell, D. R., Vesely, S. K., & George, J. N. (2013) · Blood · doi:10.1182/blood-2013-04-496752 · Cited by 220
Self-citationRelationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse
Jin, M., Casper, T. C., Cataland, S. R., Kennedy, M. S., Lin, S., Li, Y. J., & Wu, H. M. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07107.x · Cited by 148
Self-citationCallewaert, F., Roodt, J. P., Ulrichts, H., Stöhr, T., van Rensburg, W. J. J., Lamprecht, S., Rossenu, S., Priem, S., Willems, W. F., & Holz, J.-B. (2012) · Blood · doi:10.1182/blood-2012-04-420943 · Cited by 142
Self-citationPeyvandi, F., Scully, M., Hovinga, J. A. K., Knöbl, P., Cataland, S. R., Beuf, K. D., Callewaert, F., Winter, H. A. M. D., & Zeldin, R. K. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13716 · Cited by 132
Self-citationCataland, S. R., Yang, S., Witkoff, L., Kraut, E. H., Lin, S., George, J. N., & Wu, H. M. (2009) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2009.01331.x · Cited by 26
Self-citation
Cited by
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Padmanabhan, A., Connelly‐Smith, L., Aqui, N., Balogun, R. A., Klingel, R., Meyer, E., Pham, H. P., Schneiderman, J., Witt, V., Wu, Y., et al. (2019) · Journal of Clinical Apheresis · doi:10.1002/jca.21705 · Cited by 2,230
The therapeutic potential of nanobodies
Jovčevska, I., & Muyldermans, S. (2020) · BioDrugs · doi:10.1007/s40259-019-00392-z · Cited by 749
Connelly‐Smith, L., Alquist, C. R., Aqui, N. A., Hofmann, J. C., Klingel, R., Onwuemene, O. A., Patriquin, C. J., Pham, H. P., Sanchez, A. P., Schneiderman, J., et al. (2023) · Journal of Clinical Apheresis · doi:10.1002/jca.22043 · Cited by 684
KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS
Rovin, B. H., Ayoub, I. M., Chan, T. M., Liu, Z.-H., Mejía-Vilet, J. M., & Floege, J. (2024) · Kidney International · doi:10.1016/j.kint.2023.09.002 · Cited by 517
Metadata
- Authors
- Scully, M., Cataland, S. R., Peyvandi, F., Coppo, P., Knöbl, P., Kremer Hovinga, J. A., Metjian, A., de la Rubia, J., Pavenski, K., Callewaert, F., Biswas, D., De Winter, H., & Zeldin, R. K.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-01-24
- Volume
- 380
- Issue
- 4
- Pages
- 335-346
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2910737538
- Cited by
- 1,025
- References
- 13
- FWCI
- 39.33
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.